Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 1—January 2012
CME ACTIVITY - Research

Accelerating Control of Pertussis in England and Wales

Helen CampbellComments to Author , Gayatri Amirthalingam, Nick Andrews, Norman K. Fry, Robert C. George, Timothy Harrison, and Elizabeth Miller
Author affiliations: Health Protection Agency, London, UK

Main Article

Table 5

Estimated effectiveness of a 3-dose pertussis vaccine schedule among case-patients with serology-confirmed pertussis, by vaccine cohort and age group, England, 2002–2009*

Vaccine cohort† Age group of pertussis case-patients
12–39 mo
5–9 y
10–16 y
No. vaccinated/ no. total % VE (95% CI) No. vaccinated/ no. total % VE (95% CI) No. vaccinated/ no. total % VE (95% CI)
1 28/29 −41.3
(−5,679 to 76.6)
2 1/1 88/108 90.4‡
(83.4 to 94.1) 463/500 72.1‡
(59.9 to 80.1)
3 2/2 26/33 91.0§
(75.4 to 96.2)
4 2/4 97.7
(67.6 to 99.8) 4/5 90.9§
(−348 to 99.1)
5 21/25 69
(−24.2 to 89.5)
Overall total 26/32 77.8
(34.2 to 91.1) 118/146 90.5
(85.1 to 93.8) 491/529 69.3
(56.1 to 78.0)

*VE, vaccine effectiveness; –, no cases that met the criteria were identified during 2002–2009 and, therefore, VE could not be calculated, or case nos. were too small for calculation purposes.
†Vaccine cohorts: cohort 1, received diphtheria/tetanus/whole-cell pertussis vaccine (DTwP) at 3, 5, and 11 mo of age; cohort 2, received DTwP at 2, 3, and 4 mo of age; cohort 3, received DTwP or DTaP3 (DT/3-component acellular pertussis vaccine) at 2, 3, and 4 mo of age; cohort 4, received DTwP at 2, 3, 4 mo of age; cohort 5, received DTaP5 at 2, 3, and 4 mo of age.
‡VE mainly reflects 3 doses; however, some eligible children had received 4 doses.
§Some children were eligible for a booster vaccination; thus, VE is for 3 or 4 doses.

Main Article

Page created: December 23, 2011
Page updated: December 23, 2011
Page reviewed: December 23, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external